BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 34807464)

  • 1. Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (LICC, CELIM, FIRE-3).
    Moehler M; Folprecht G; Heinemann V; Holch JW; Maderer A; Kasper S; Hegewisch-Becker S; Schröder J; Overkamp F; Kullmann F; Bechstein WO; Vöhringer M; Öllinger R; Lordick F; Geißler M; Schulz-Abelius A; Linz B; Bernhard H; Paul A; Schmidtmann I; Potthoff K; Schimanski CC
    Int J Cancer; 2022 Apr; 150(8):1341-1349. PubMed ID: 34807464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC).
    Schimanski CC; Kasper S; Hegewisch-Becker S; Schröder J; Overkamp F; Kullmann F; Bechstein WO; Vöhringer M; Öllinger R; Lordick F; Heinemann V; Geißler M; Schulz-Abelius A; Bernhard H; Schön MR; Greil R; Galle P; Lang H; Schmidtmann I; Moehler M
    Oncoimmunology; 2020 Aug; 9(1):1806680. PubMed ID: 32923171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial.
    Schimanski CC; Möhler M; Schön M; van Cutsem E; Greil R; Bechstein WO; Hegewisch-Becker S; von Wichert G; Vöhringer M; Heike M; Heinemann V; Peeters M; Kanzler S; Kasper S; Overkamp F; Schröder J; Seehofer D; Kullmann F; Linz B; Schmidtmann I; Smith-Machnow V; Gockel I; Lang H; Galle PR
    BMC Cancer; 2012 Apr; 12():144. PubMed ID: 22494623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of prognostic factors in liver-limited metastatic colorectal cancer: a preplanned analysis of the FIRE-1 trial.
    Giessen C; Fischer von Weikersthal L; Laubender RP; Stintzing S; Modest DP; Schalhorn A; Schulz C; Heinemann V
    Br J Cancer; 2013 Sep; 109(6):1428-36. PubMed ID: 23963138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial.
    Holch JW; Ricard I; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Kullmann F; Scheithauer W; Scholz M; Müller S; Link H; Rost A; Höffkes HG; Moehler M; Lindig RU; Miller-Phillips L; Kirchner T; Jung A; von Einem JC; Modest DP; Heinemann V
    Int J Cancer; 2018 Mar; 142(5):1047-1055. PubMed ID: 29047142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Centralized repeated resectability assessment of patients with colorectal liver metastases during first-line treatment: prospective study.
    Isoniemi H; Uutela A; Nordin A; Lantto E; Kellokumpu I; Ovissi A; Kosunen J; Kallio R; Soveri LM; Salminen T; Ålgars A; Lamminmäki A; Halonen P; Ristamäki R; Räsänen J; Karjula H; Vaalavuo Y; Lavonius M; Osterlund P
    Br J Surg; 2021 Jul; 108(7):817-825. PubMed ID: 33749772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updated long-term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy.
    Kemeny NE; Chou JF; Boucher TM; Capanu M; DeMatteo RP; Jarnagin WR; Allen PJ; Fong YC; Cercek A; D'Angelica MI
    J Surg Oncol; 2016 Apr; 113(5):477-84. PubMed ID: 26830685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does "conversion chemotherapy" really improve survival in metastatic colorectal cancer patients with liver-limited disease?
    Kataoka K; Kanazawa A; Iwamoto S; Kato T; Nakajima A; Arimoto A
    World J Surg; 2014 Apr; 38(4):936-46. PubMed ID: 24166026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52.
    Bolton JS; O'Connell MJ; Mahoney MR; Farr GH; Fitch TR; Maples WJ; Nagorney DM; Rubin J; Fuloria J; Steen PD; Alberts SR
    Clin Colorectal Cancer; 2012 Mar; 11(1):31-7. PubMed ID: 21729678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).
    Folprecht G; Gruenberger T; Bechstein W; Raab HR; Weitz J; Lordick F; Hartmann JT; Stoehlmacher-Williams J; Lang H; Trarbach T; Liersch T; Ockert D; Jaeger D; Steger U; Suedhoff T; Rentsch A; Köhne CH
    Ann Oncol; 2014 May; 25(5):1018-25. PubMed ID: 24585720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significant increase of synchronous disease in first-line metastatic colorectal cancer trials: Results of a systematic review.
    Goey KK; 't Lam-Boer J; de Wilt JH; Punt CJ; van Oijen MG; Koopman M
    Eur J Cancer; 2016 Dec; 69():166-177. PubMed ID: 27821320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary Metastases Resection After Bevacizumab Plus Irinotecan-Based Chemotherapy in First-Line Therapy of Metastatic Colorectal Cancer in a Real-Life Setting: Results of the ETNA Cohort.
    Rouyer M; Smith D; Laurent C; Becouarn Y; Guimbaud R; Michel P; Tubiana-Mathieu N; Balestra A; Jové J; Robinson P; Noize P; Moore N; Ravaud A; Fourrier-Réglat A;
    Target Oncol; 2016 Feb; 11(1):83-92. PubMed ID: 26298481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973).
    Goéré D; Pignon JP; Gelli M; Elias D; Benhaim L; Deschamps F; Caramella C; Boige V; Ducreux M; de Baere T; Malka D
    BMC Cancer; 2018 Aug; 18(1):787. PubMed ID: 30081865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab.
    Bruera G; Cannita K; Giuliante F; Lanfiuti Baldi P; Vicentini R; Marchetti P; Nuzzo G; Antonucci A; Ficorella C; Ricevuto E
    Clin Colorectal Cancer; 2012 Jun; 11(2):119-26. PubMed ID: 22206922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of extensive metastatic colorectal cancer to the liver with systemic and hepatic arterial infusion chemotherapy and two-stage hepatic resection: the role of salvage therapy for recurrent disease.
    Cardona K; Donataccio D; Kingham TP; Allen PJ; DeMatteo RP; Fong Y; Jarnagin WR; Cercek A; Kemeny NE; D'Angelica MI
    Ann Surg Oncol; 2014 Mar; 21(3):815-21. PubMed ID: 24242675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of microscopic incomplete resection (R1) of colorectal liver metastases in the era of neoadjuvant chemotherapy.
    Ayez N; Lalmahomed ZS; Eggermont AM; Ijzermans JN; de Jonge J; van Montfort K; Verhoef C
    Ann Surg Oncol; 2012 May; 19(5):1618-27. PubMed ID: 22006375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903.
    Posner MC; Niedzwiecki D; Venook AP; Hollis DR; Kindler HL; Martin EW; Schilsky RL; Goldberg RM; Mayer RJ
    Ann Surg Oncol; 2008 Jan; 15(1):158-64. PubMed ID: 18008108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
    Cremolini C; Casagrande M; Loupakis F; Aprile G; Bergamo F; Masi G; Moretto R R; Pietrantonio F; Marmorino F; Zucchelli G; Tomasello G; Tonini G; Allegrini G; Granetto C; Ferrari L; Urbani L; Cillo U; Pilati P; Sensi E; Pellegrinelli A; Milione M; Fontanini G; Falcone A
    Eur J Cancer; 2017 Mar; 73():74-84. PubMed ID: 27986363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases - the multicenter randomized controlled PUMP trial.
    Buisman FE; Homs MYV; Grünhagen DJ; Filipe WF; Bennink RJ; Besselink MGH; Borel Rinkes IHM; Bruijnen RCG; Cercek A; D'Angelica MI; van Delden OM; Donswijk ML; van Doorn L; Doornebosch PG; Emmering J; Erdmann JI; IJzerman NS; Grootscholten C; Hagendoorn J; Kemeny NE; Kingham TP; Klompenhouwer EG; Kok NFM; Koolen S; Kuhlmann KFD; Kuiper MC; Lam MGE; Mathijssen RHJ; Moelker A; Oomen-de Hoop E; Punt CJA; Te Riele WW; Roodhart JML; Swijnenburg RJ; Prevoo W; Tanis PJ; Vermaas M; Versleijen MWJ; Veuger FP; Weterman MJ; Verhoef C; Groot Koerkamp B
    BMC Cancer; 2019 Apr; 19(1):327. PubMed ID: 30953467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).
    Carrato A; Abad A; Massuti B; Grávalos C; Escudero P; Longo-Muñoz F; Manzano JL; Gómez A; Safont MJ; Gallego J; García-Paredes B; Pericay C; Dueñas R; Rivera F; Losa F; Valladares-Ayerbes M; González E; Aranda E;
    Eur J Cancer; 2017 Aug; 81():191-202. PubMed ID: 28633089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.